Starting a Company Is Hard. Good Health Insurance Makes It Easier.

I didn’t want to have a gap in my health insurance while I was working on this. I also didn’t want to feel rushed into a situation that wasn’t quite right or stop chasing the ideas I was developing just because I felt urgency to get health insurance. A friend suggested I look at MHC.

After 45 minutes on the website, I felt tremendous relief. I knew that there was a solution there. And not just a solution, but a wide variety of choices. It was an incredible feeling to know that I could continue to pursue my entrepreneurial goals without having to worry about whether I was taking an unnecessary risk with my own health.

Beyond that, I had a truly excellent experience using MHC. How often do you get to say great things about your government? I think most of us take it as a given that you’re just supposed to complain about government (I’m human, I have those moments too). But not this time. Credit where credit is due: Great program, great people, great service, great outcome. It was also efficient and easy, which I also appreciate. (They also have a fascinating series of toolkits for implementing a program like this.)

I honestly hadn’t realized how much health insurance had been preying on my mind until I slept so well that night.

I know I’m not the typical customer. I do have financial resources, and healthcare coverage can still be expensive (though my new plan is actually cheaper than what I was paying for under my old COBRA plan…for the same kind of coverage & my same doctors). That’s still a challenge for our whole society, and as someone who works in the biotech and pharmaceutical industry, I understand the complexity of this challenge.

But in case anyone was wondering whether there’s a real connection between healthcare coverage and entrepreneurship, the answer is definitively yes.

It makes it easier.

Author: Katrine Bosley

Katrine Bosley is the CEO of Editas Medicine and the former CEO of Avila Therapeutics, a company that championed the discovery and development of targeted covalent drugs. Avila established alliances with Sanofi, Clovis Oncology, and the Leukemia & Lymphoma Society and advanced two programs into clinical development, one independently and one with partner Clovis, prior to its acquisition by Celgene in early 2012 ($350 million upfront + $575 million contingent on milestones). Prior to her leadership at Avila, Katrine was VP, Business Development at Adnexus Therapeutics, a company developing a new class of protein therapeutics called Adnectins. Adnexus was acquired by Bristol-Myers Squibb in 2007 (>$500 million). Katrine joined Adnexus from Biogen Idec where she led multiple business development transactions, including the in-licensing of Tysabri® (natalizumab). Earlier, she was part of the healthcare team at the venture firm Highland Capital Partners and was in regulatory affairs at Alkermes. Through her career, Katrine has worked with products from discovery through commercialization. Katrine graduated from Cornell University with a B.A. in biology as a College Scholar and completed the Program for Management Development at Harvard Business School.